BlueSphere Bio's TCXpress platform revolutionises the isolation and functional characterisation of T-cell receptors (TCRs) with unparalleled speed and efficiency, enabling rapid identification of unique TCRs from thousands of individual T cells within days.
List view / Grid view
Myelodysplastic syndromes (MDS)
Professor Ulrich G Steidl received the National Institute of Cancer's Outstanding Investigator Award to study myelodysplastic syndromes (MDS) and acute myeloid leukaemia (AML).
Researchers have uncovered how mutations affecting RNA splicing alter cells to develop myelodysplastic syndrome (MDS).
Researchers have discovered a potential new strategy for treating myelodysplastic syndrome, which has shown to be successful in pre-clinical trials.
24 March 2016 | By Victoria White
Apogenix’s APG101 rescues the production of red blood cells (erythropoiesis) in bone marrow samples from patients with lower-risk myelodysplastic syndromes...